Company Overview
Snapshot
Founded in February 2024 by Eitan Rubinow, GenoCure.AI operates with 1–10 employees. The company has secured $520,000 in total capital across one funding round from one investor, reaching a Pre-Seed stage. In September 2024, GenoCure.AI received funding from Hadasit.
Business overview
GenoCure.AI is an oncology-focused company that leverages artificial intelligence and deep genomic analysis to develop personalized cancer treatment strategies. The company's core product, the Supreme™ Platform, integrates multi-omic data with AI-driven algorithms to identify effective therapeutic combinations tailored to individual patient tumor profiles. GenoCure.AI serves physicians, healthcare providers, and pharmaceutical companies, aiming to bridge the gap between scientific discoveries and clinical applications within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology.
Log in to access full profile ›Company Intelligence Q&A
- When was GenoCure.AI founded?
- GenoCure.AI was founded in February 2024.
- Who is the founder of GenoCure.AI?
- Eitan Rubinow is the founder of GenoCure.AI.
- What is GenoCure.AI's primary focus?
- GenoCure.AI focuses on transforming oncology by integrating advanced AI with deep genomic analysis to personalize cancer treatment strategies.
- What is the Supreme™ Platform?
- The Supreme™ Platform is GenoCure.AI's proprietary system that combines multi-omic data with AI-driven algorithms to identify effective therapeutic combinations tailored to each patient's unique tumor profile.